The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,346K data for 622K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

76 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Design and synthesis of potent, selective phenylimidazole-based FVIIa inhibitors.EBI
Bristol-Myers Squibb R & D
Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties.EBI
Bristol-Myers Squibb
Phenylimidazoles as potent and selective inhibitors of coagulation factor XIa with in vivo antithrombotic activity.EBI
Bristol-Myers Squibb
Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor.EBI
Chinese Academy Of Sciences
Synthesis and biological evaluation of direct thrombin inhibitors bearing 4-(piperidin-1-yl)pyridine at the P1 position with potent anticoagulant activity.EBI
University Of Bari &Quot;Aldo Moro&Quot
Discovery of nonbenzamidine factor VIIa inhibitors using a biaryl acid scaffold.EBI
Bristol-Myers Squibb Research & Development
Discovery and gram-scale synthesis of BMS-593214, a potent, selective FVIIa inhibitor.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Discovery of diarylurea P2Y(1) antagonists with improved aqueous solubility.EBI
Bristol-Myers Squibb
Design and synthesis of selective keto-1,2,4-oxadiazole-based tryptase inhibitors.EBI
Celera Genomics
Potent direct inhibitors of factor Xa based on the tetrahydroisoquinoline scaffold.EBI
Virginia Commonwealth University
Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.EBI
Johnson & Johnson Pharmaceutical Research & Development
SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation Factor Xa.EBI
Bristol-Myers Squibb
Solid-phase synthesis of naphthylamidines as factor VIIa/tissue factor inhibitors.EBI
Berlex Biosciences
Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1).EBI
Pharmaceutical Research Institute
Polymer-assisted solution-phase library synthesis and crystal structure of alpha-ketothiazoles as tissue factor VIIa inhibitors.EBI
Pharmacia
Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa.EBI
Dupont Pharmaceuticals
Polymer-assisted solution-phase (PASP) parallel synthesis of an alpha-ketothiazole library as tissue factor VIIa inhibitors.EBI
Pharmacia
Targeting thrombin and factor VIIa: design, synthesis, and inhibitory activity of functionally relevant indolizidinones.EBI
Universit£
Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors.EBI
Bristol-Myers Squibb
Design, synthesis and biological activity of novel peptidyl benzyl ketone FVIIa inhibitors.EBI
Technical University Of Denmark
Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif.EBI
Johnson & Johnson Pharmaceutical Research And Development
Preparation of L-proline based aeruginosin 298-A analogs: optimization of the P1-moiety.EBI
University Of New Orleans
 
Synthesis and biological activity of P2–P4 azapeptidomimetic P1-argininal and P1-ketoargininamide derivatives: a novel class of serine protease inhibitorsEBI
TBA
Discovery of N-[(1R,2S,5S)-2-{[(5-chloroindol-2-yl)carbonyl]amino}-5-(dimethylcarbamoyl)cyclohexyl]-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide hydrochloride: a novel, potent and orally active direct inhibitor of factor Xa.EBI
Daiichi Sankyo
Factor VIIa inhibitors: target hopping in the serine protease family using X-ray structure determination.EBI
Chugai Pharmaceutical
Dysinosins B-D, inhibitors of factor VIIa and thrombin from the Australian sponge Lamellodysidea chlorea.EBI
Griffith University
7-fluoroindazoles as potent and selective inhibitors of factor Xa.EBI
Johnson & Johnson Pharmaceutical Research And Development
Enantiopure five-membered cyclicdiamine derivatives as potent and selective inhibitors of factor Xa. Improving in vitro metabolic stability via core modifications.EBI
Bristol-Myers Squibb
Design, synthesis, and biological evaluation of pyrazinones containing novel P1 needles as inhibitors of TF/VIIa.EBI
Pfizer
Design of novel, potent, and selective human beta-tryptase inhibitors based on alpha-keto-[1,2,4]-oxadiazoles.EBI
Celera
Efforts toward oral bioavailability in factor VIIa inhibitors.EBI
Celera
Factor VIIa inhibitors: a prodrug strategy to improve oral bioavailability.EBI
Celera Genomics
Generation of potent coagulation protease inhibitors utilizing zinc-mediated chelation.EBI
Celera
Ketene aminal-based lactam derivatives as a novel class of orally active FXa inhibitors.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Structure-based design and synthesis of pyrazinones containing novel P1 'side pocket' moieties as inhibitors of TF/VIIa.EBI
Pfizer
Structure-based design of amidinophenylurea-derivatives for factor VIIa inhibition.EBI
Aventis Pharma Deutschland
Synthesis and X-ray crystal structures of substituted fluorobenzene and benzoquinone inhibitors of the tissue factor VIIa complex.EBI
Pharmacia
Phosphate ester serum albumin affinity tags greatly improve peptide half-life in vivo.EBI
Genentech
Design, synthesis, and structure-activity relationship of a new class of amidinophenylurea-based factor VIIa inhibitors.EBI
Aventis Pharma Deutschland
Structure-activity relationship study and drug profile of N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal (SJA6017) as a potent calpain inhibitor.EBI
Senju Pharmaceutical
Albumin affinity tags increase peptide half-life in vivo.EBI
Genentech
Exploiting subsite S1 of trypsin-like serine proteases for selectivity: potent and selective inhibitors of urokinase-type plasminogen activator.EBI
Axys Pharmaceuticals
Optimization of a screening lead for factor VIIa/TF.EBI
Axys Pharmaceuticals
Secondary structure peptide mimetics: design, synthesis, and evaluation of beta-strand mimetic thrombin inhibitors.EBI
Molecumetics
Preparation of meta-amidino-N,N-disubstituted anilines as potent inhibitors of coagulation factor Xa.EBI
Dupont Pharmaceuticals
Pyrazoles, 1,2,4-triazoles, and tetrazoles as surrogates for cis-amide bonds in boronate ester thrombin inhibitors.EBI
Dupont Pharmaceuticals
Pharmacological and biochemical characterization of a recombinant human galanin GALR1 receptor: agonist character of chimeric galanin peptides.BDB
Dupont Pharmaceuticals
The cloned guinea pig pancreatic polypeptide receptor Y4 resembles more the human Y4 than does the rat Y4.BDB
Uppsala University
Structure-based design and combinatorial chemistry yield low nanomolar inhibitors of cathepsin D.BDB
University Of California Berkeley
Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function.BDB
Dana-Farber Cancer Institute
Design, synthesis and selection of DNA-encoded small-molecule libraries.BDB
Praecis Pharmaceuticals
Molecular docking and ligand specificity in fragment-based inhibitor discovery.BDB
University Of California San Francisco
Indene-based frameworks targeting the 5-HT6 serotonin receptor: ring constraint in indenylsulfonamides using cyclic amines and structurally abbreviated counterparts.BDB
Universitat De Barcelona